Obese, Overweight
Conditions
Keywords
high complex carbohydrates, hypocaloric diet, cholinergic status, overweight, obese
Brief summary
The investigators aims in the current study are to examine whether the cholinergic status should be considered as another risk factor for the metabolic syndrome and it's co-morbidities and to test the effect of a hypocaloric high complex carbohydrates diet on the cholinergic status of overweight and obese adults with and without the metabolic syndrome.
Detailed description
Intervention studies have demonstrated that the autonomic disturbances of the metabolic syndrome may be reversible. A reduction in body weight induced by a hypocaloric diet exerts a marked reduction in sympathetic activity in obese people with or without metabolic syndrome. Incorporation of regular, moderate intensity aerobic exercise training during a dietary weight loss program does not confer additional benefits on resting sympathetic neural activity, compared with weight loss by diet alone. A new method has been developed to examine the sympathetic-parasympathetic status of an individual - the cholinergic status. Cholinergic Status represents the total soluble circulation capacity for acetylcholine hydrolysis. Higher cholinergic status means the individual is more sympathetic . A cross sectional study that took place in Tel Aviv Sorasky medical center and included 632 participants found that the cholinergic status is related to metabolic syndrome parameters in a dose response manner and that it correlates significantly with glucose,HbA1c, lipid profile and hs-CRP.
Interventions
BEHAVIORALhigh complex carbohydrates diet given in a diet group
diet groups that meet every week for eight weeks or more.
Sponsors
Tel-Aviv Sourasky Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* BMI ≥ 25kg/m2 * Stable weight (±1kg)in the previous six months * Non smokers
Exclusion criteria
* Type II diabetes * Hypertension pharmacologically treated * Cardiovascular disease * Renal disease * Cirrhosis and end-stage liver failure * Thyroid disease * Cerebrovascular disease * Cancer * Autoimmune disease * Chronic inflammatory disease * Surgery or heart catheterization in the previous six months * Use of drugs known to affect measured parameters
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total soluble circulation capacity for acetylcholine hydrolysis | 8 weeks or more |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory markers | 8 weeks or more | hs-CRP, ESR, Fibrinogen, IL-1b, IL-6, TNF-α |
| ROTEM - rotation thromboelastometry | 8 weeks or more | ROTEM documents the interaction of platelets with the coagulation factors from initial platelet-fibrin interaction, through platelet aggregation, clot strengthening and fibrin cross-linking to eventual clot lysis. Within 30 min, a ROTEM tracing provides information on clotting factor activity, platelet function and any clinically significant fibrinolysis. |
| Metabolic markers | 8 weeks or more | Fasting Glucose, HbA1c,Insulin, lipid profile |
Outcome results
None listed